We aim to relieve the suffering associated with chronic pain by creating treatments that address the safety and efficacy gaps in the current treatment paradigm.
Location: United States, Massachusetts, Boston
Total raised: $67M
Investors 4
| Date | Name | Website |
| 06.07.2021 | New Enterp... | nea.com |
| - | Alta Partn... | altapartne... |
| - | InterWest ... | interwest.... |
| - | Presidio P... | presidiopa... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 03.01.2018 | Series D | $67M | New Enterp... |
Mentions in press and media 20
| Date | Title | Description |
| 29.10.2020 | Centrexion Therapeutics Raises $40.5 Million | BOSTON, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Centrexion Therapeutics Corporation, a biotechnology company focused on developing and commercializing non-opioid, non-addictive chronic pain drugs and in-licensing undervalued mid-stage drug candid... |
| 29.10.2020 | CENTREXION THERAPEUTICS CORPORATION Centrexion Therapeutics Raises $40.5 Million and Adds Lilly and Exome Asset Management as New Investors | BOSTON, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Centrexion Therapeutics Corporation, a biotechnology company focused on developing and commercializing non-opioid, non-addictive chronic pain drugs and in-licensing undervalued mid-stage drug candid... |
| 28.05.2019 | A bruised Eli Lilly buys rights to Centrexion's early-stage pain drug for $47.5M upfront | Eli Lilly is working on putting its woes in the rearview mirror. In recent months, a late-stage failure triggered the withdrawal of its cancer drug Lartruvo, the US drugmaker relegated two mid-stage drugs to the scrap heap, a... |
| 15.11.2018 | Centrexion Therapeutics changes its mind on initial public offering | “The company has decided not to move forward with an IPO at this time given current market conditions,” an emailed statement from the company read. Renaissance Capital had reported earlier in the day that the Boston-based company had decide... |
| 03.01.2018 | Centrexion’s $67M Series D round to fund Phase 3 pain studies | Despite being just four years old, Centrexion is building a significant pipeline of non-opioid, non-steroidal pain medications. CNTX-4975 is being developed to treat pain from osteoarthritis and Morton’s Neuroma. The drug is a synthetic tra... |
| 03.01.2018 | Term Sheet — Wednesday, January 3 | 5 Qs WITH A DEALMAKER Eric Hippeau, a managing partner at Lerer Hippeau Ventures, is well-known in the venture community for his firm’s blockbuster investments including Birchbox, BuzzFeed, Casper, and Warby Parker. Two thirds of Lerer Hipp... |
| 02.01.2018 | Centrexion Therapeutics Raises $67M in Series D Financing | Centrexion Therapeutics Corporation, a Boston, MA-based company focused on developing non-opioid, non-steroidal therapeutics for the treatment of chronic pain, completed a $67m Series D financing. The round was led by New Enterprise Associa... |
| 02.01.2018 | Centrexion Therapeutics Raises $67M Series D | BOSTON, MA, Company focused on developing non-opioid, non-steroidal therapeutics for the treatment of chronic pain, has completed a $67M Series D financing. >> Click here for more funding data on Centrexion Therapeutics >> T... |
| 02.01.2018 | NEA Leads $67M Series D for Centrexion | BOSTON--(BUSINESS WIRE)--Centrexion Therapeutics Corporation, a company focused on developing non-opioid, non-steroidal therapeutics for the treatment of chronic pain, today announced the successful completion of a $67 million Series D fina... |
| 02.01.2018 | Kindler’s Centrexion raises $67M to fund phase 3 pain trial | Centrexion Therapeutics has raised $67 million. The Jeffrey Kindler-helmed biotech will use the cash to move nonopioid pain drug CNTX-4975 into a phase 3 trial in patients with knee osteoarthritis in the coming months. Sponsored by Agilent ... |
Show more